SAFFRON
Start here
The global Phase III SAFFRON trial evaluated osimertinib combined with savolitinib against platinum doublet chemotherapy in patients with MET-altered, EGFR-mutated non-small cell lung cancer. The combination reduced the risk of disease progression or death by 45%, with a progression-free survival hazard ratio of 0.55 (95% CI 0.42-0.72; p<0.001). The results position the osimertinib-savolitinib pairing as a potential option for this biomarker-defined population after EGFR-directed therapy. Questions that remain open include full survival data, safety and tolerability details beyond the headline efficacy figure, and whether regulators will act on the findings.
Written by a model from the reports · updated 1 hour ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickSAFFRON Global Phase III: Osimertinib Plus Savolitinib Cuts Risk of Progression or Death 45% in MET-Altered EGFR-Mutant Lung Cancer
The global Phase III SAFFRON trial showed that osimertinib combined with savolitinib reduced the risk of disease progression or death by 45% versus platinum doublet chemotherapy in MET-altered, EGFR-mutated NSCLC (PFS HR 0.55; 95% CI 0.42-0.72; p<0.001).
- x.com#ESMO26 | SAFFRON
- x.comSAFFRON x MARIPOSA 2
- x.com#ESMO26 | SAFFRON
- x.com#ESMO26
- x.com#ESMO26 | LBA6
Heat trend for this story
Heat now 251·Peak in the comparable set 301 (Oct 26 06:00)·Change over 24h in the comparable set -13%·Participants now 47
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.